APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

15 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

12 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

10 Nov 2021 06:00:04 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

08 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting

04 Nov 2021 08:17:31 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

03 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results

01 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH

15 Oct 2021 06:17:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting

30 Sep 2021 10:49:32 By Nasdaq GlobeNewswire